TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11127934

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thienopyridines (ticlopidine and clopidogrel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platelet glycoprotein IIb/IIIa inhibitors
Number of subjects: 0
Study: 8839667

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg t.i.d.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo t.i.d.
Number of subjects: 20
Study: 1538721

Group type: EXPERIMENTAL
Intervention: Continuous medical therapy (lifestyle modifications and up to four medications)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Medical therapy for symptoms only
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Surgical therapy (Nissen fundoplication)
Number of subjects: 247
Study: 6437310

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 0
Study: 31396834

Group type: EXPERIMENTAL
Intervention: MSB11022
Number of subjects: 288

Group type: COMPARATOR
Intervention: Reference adalimumab
Number of subjects: 288
Study: 28595367

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 259

Group type: COMPARATOR
Intervention: No Ultrasonography (without US)
Number of subjects: 259
Study: 26859076

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs)
Number of subjects: 1525

Group type: COMPARATOR
Intervention: Interferon‐α only
Number of subjects: 1525

Group type: EXPERIMENTAL
Intervention: All malignancies excluding non‐melanoma skin tumors
Number of subjects: 1525

Group type: EXPERIMENTAL
Intervention: Colorectal cancer in men
Number of subjects: 1525

Group type: EXPERIMENTAL
Intervention: Non-Hodgkin's lymphoma (NHL) in women
Number of subjects: 1525

Group type: EXPERIMENTAL
Intervention: NHL
Number of subjects: 1525

Group type: EXPERIMENTAL
Intervention: Secondary malignancies overall
Number of subjects: 1525
Study: 24419307

Group type: EXPERIMENTAL
Intervention: EVP-6124 0.3 mg (n=8)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: EVP-6124 1.0 mg (n=9)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (n=4)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: EVP-6124 (0.3 mg and 1.0 mg)
Number of subjects: 21
Study: 22023670

Group type: EXPERIMENTAL
Intervention: Alcohol mixed with energy drinks (AmED)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Alcohol alone
Number of subjects: 18
Study: 19941582

Group type: EXPERIMENTAL
Intervention: TASK intervention (n=21)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Attention control group (n=19)
Number of subjects: 40
Study: 17516769

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motivational therapy
Number of subjects: 0
Study: 16225570

Group type: EXPERIMENTAL
Intervention: Debriefing sessions by community midwives at 10 days and 10 weeks
Number of subjects: 319

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Debriefing sessions by community midwives at 10 weeks
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Debriefing sessions by community midwives at 20 weeks
Number of subjects: 319
Study: 12405434

Group type: EXPERIMENTAL
Intervention: Early interventional therapy
Number of subjects: 190

Group type: COMPARATOR
Intervention: No program (Control)
Number of subjects: 190
Study: 10091789

Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m2) followed by IL-2 (18 x 10(6) IU/m2) on Days 3-6 and Days 17-21 (Arm 1)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Cisplatin and IL-2 with subcutaneous IFN (9 x 10(6) U, 3 times a week during IL-2 administration) (Arm 2)
Number of subjects: 117
Study: 8573537

Group type: EXPERIMENTAL
Intervention: Weekly dose-intensive chemotherapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: 3-weekly conventional chemotherapy
Number of subjects: 75
Study: 2303577

Group type: EXPERIMENTAL
Intervention: Gemfibrozil alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Gemfibrozil with colestipol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 2 hours before colestipol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 2 hours after colestipol
Number of subjects: 10
Study: 465271

Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg with Diazepam 5 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Droperidol 10 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Larger doses of droperidol with diazepam
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Larger doses of diazepam with droperidol
Number of subjects: 240
Study: 30595113

Group type: EXPERIMENTAL
Intervention: Relationship enhancement education and counseling (REEC) program
Number of subjects: 32

Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 32
Study: 28632106

Group type: EXPERIMENTAL
Intervention: Speed-Interactive Treadmill Training (SITT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard Treadmill Training (Control)
Number of subjects: 34
Study: 25650142

Group type: EXPERIMENTAL
Intervention: Haytoglu et al.'s modification of incisionless otoplasty technique
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fritsch's incisionless otoplasty technique
Number of subjects: 60
Study: 22561646

Group type: EXPERIMENTAL
Intervention: Venus Flow resin-cement coating
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Rely-X Veneer resin-cement coating
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Clearfil Majesty Posterior resin-cement coating
Number of subjects: 240
Study: 21266516

Group type: EXPERIMENTAL
Intervention: Irinotecan 50 mg/m2 on days 1, 8, and 15 combined with carboplatin AUC 5 mg x min/ml
Number of subjects: 216

Group type: COMPARATOR
Intervention: Etoposide 140 mg/m2 on days 1-3 combined with carboplatin AUC 5 mg x min/ml
Number of subjects: 216
Study: 19812336

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17605747

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional amphotericin B (CAB)
Number of subjects: 0
Study: 15500532

Group type: EXPERIMENTAL
Intervention: Acupressure at Sanyinjiao point
Number of subjects: 69

Group type: COMPARATOR
Intervention: Rest for 20 minutes (Control)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Acupressure at Sanyinjiao point (self-treatment follow-up)
Number of subjects: 69
Study: 11488995

Group type: EXPERIMENTAL
Intervention: Ovarian cancer screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9630110

Group type: EXPERIMENTAL
Intervention: Ibutilide low dose (0.005 mg/kg + 0.001 mg/kg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Ibutilide middle dose (0.01 mg/kg + 0.002 mg/kg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Ibutilide high dose (0.02 mg/kg + 0.004 mg/kg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Ibutilide (all doses)
Number of subjects: 55
Study: 7526774

Group type: EXPERIMENTAL
Intervention: Low doses of oral corticosteroids
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Early awareness of potential injuries to shoulder joint structures
Number of subjects: 132
Study: 2464722

Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 333

Group type: COMPARATOR
Intervention: Conventional topical hemostatic agent
Number of subjects: 333
Study: 954013

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and methyl-CCNU
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracil
Number of subjects: 0
Study: 30280464

Group type: EXPERIMENTAL
Intervention: Antegrade technique
Number of subjects: 330

Group type: COMPARATOR
Intervention: Retrograde technique
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 330
Study: 29043998

Group type: EXPERIMENTAL
Intervention: Trabeculectomy (operation group)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Antiglaucoma medication (drug group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Water drinking test (WDT)
Number of subjects: 55
Study: 25796102

Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 0
Study: 22850760

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pitavastatin 2 mg orally with water
Number of subjects: 12
Study: 22092836

Group type: EXPERIMENTAL
Intervention: Honey-coated bandages
Number of subjects: 69

Group type: COMPARATOR
Intervention: Silver-coated bandages
Number of subjects: 69
Study: 19657720

Group type: EXPERIMENTAL
Intervention: Videoconference training course (4 courses, 13 synchronous sessions)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Videoconference training course (2 or more courses attended)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Videoconference training course (attendance)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Implementation of cognitive services
Number of subjects: 225
Study: 16885723

Group type: EXPERIMENTAL
Intervention: Liquid hemp oil (0.39 and 14.8 mg THC/d)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hemp oil in capsules (0.47 mg THC/d)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dronabinol capsules (7.5 mg THC/d)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 12668794

Group type: EXPERIMENTAL
Intervention: Individualised homeopathic remedies
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 96
Study: 10838768

Group type: EXPERIMENTAL
Intervention: Kinesitherapy with Continuous Passive Motion (CPM)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Kinesitherapy without Continuous Passive Motion (CPM)
Number of subjects: 76
Study: 9357876

Group type: EXPERIMENTAL
Intervention: 0.09 mg/kg morphine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 0.09 mg/kg morphine plus 0.3 mg/kg methylnaltrexone
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 11
Study: 1376847

Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg twice daily for 3 months
Number of subjects: 10
Study: 4007415

Group type: EXPERIMENTAL
Intervention: Adenine arabinoside (Ara‐A) alone (10 mg/kg body wt for 4‐8 weeks)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Combination therapy (prednisolone 40 mg/day for 4 weeks followed by Ara‐A)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Prednisolone alone (for 4 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ara‐A alone
Number of subjects: 43
Study: 31230462

Group type: EXPERIMENTAL
Intervention: active iTBS (intermittent theta-burst stimulation)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: active iTBS
Number of subjects: 50

Group type: COMPARATOR
Intervention: sham treatment
Number of subjects: 50
Study: 29866116

Group type: EXPERIMENTAL
Intervention: pyronaridine‐artesunate (PA)
Number of subjects: 160

Group type: COMPARATOR
Intervention: artemether‐lumefantrine (AL)
Number of subjects: 160
Study: 27611806

Group type: EXPERIMENTAL
Intervention: Propofol (20 mg IV)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Midazolam (2 mg IV)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 120
Study: 23855406

Group type: EXPERIMENTAL
Intervention: Standard prenatal plus brief cognitive behavioural therapy (CBT) initiated between the 20th and 28th gestation week
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard prenatal care (control group)
Number of subjects: 42
Study: 22449251

Group type: EXPERIMENTAL
Intervention: Adefovir and lamivudine (100 mg/daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Adefovir alone (10 mg/daily)
Number of subjects: 41
Study: 20338041

Group type: EXPERIMENTAL
Intervention: Complex intervention based on the WHO 'five steps to quit' model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 18698234

Group type: EXPERIMENTAL
Intervention: COMT haplotypes (low activity A_C_C_G, medium activity A_T_C_A, high activity G_C_G_G)
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Levodopa treatment in PD patients
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: COMT haplotypes
Number of subjects: 679
Study: 11438563

Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal therapy offered to women whose tumors express hormone receptor protein
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Adjuvant polychemotherapy
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Anthracyclines in adjuvant chemotherapy regimens
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Adjuvant dose-intensive chemotherapy regimens
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Postmastectomy radiotherapy for patients with one to three positive lymph nodes
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Quality of life evaluation in selected randomized clinical trials
Number of subjects: 1000
Study: 9604191

Group type: EXPERIMENTAL
Intervention: Suture of the patellar tendon and bone grafting of the patellar defect
Number of subjects: 60

Group type: COMPARATOR
Intervention: Leaving the tendon gap and patellar defect open (Control)
Number of subjects: 60
Study: 8000218

Group type: EXPERIMENTAL
Intervention: Jian-Pi Yi-Qi Li-Shui Decoction (JPYQLSD)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Hydration treatment
Number of subjects: 95
Study: 2897806

Group type: EXPERIMENTAL
Intervention: Sufentanil 10 or 20 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sufentanil nose drops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 0
Study: 30880436

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 13
Study: 31346409

Group type: EXPERIMENTAL
Intervention: Online theory-based KT educational and brief action plan (BAP) intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: Clinical practice guideline (control group)
Number of subjects: 32
Study: 28577546

Group type: EXPERIMENTAL
Intervention: Sisterhood Method for estimating maternal mortality
Number of subjects: 7069
Study: 25997653

Group type: EXPERIMENTAL
Intervention: 40 mg/kg/day of docosahexaenoic acid (DHA)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 80 mg/kg/day of docosahexaenoic acid (DHA)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 120 mg/kg/day of docosahexaenoic acid (DHA)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Maternal DHA supplementation
Number of subjects: 31

Group type: COMPARATOR
Intervention: No supplementary DHA
Number of subjects: 31
Study: 23193009

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (1-4 capsules daily containing 277.8 mg DHA and 39.0 mg EPA)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 21787260

Group type: EXPERIMENTAL
Intervention: Lactate analysis
Number of subjects: 2992

Group type: COMPARATOR
Intervention: pH analysis
Number of subjects: 2992

Group type: COMPARATOR
Intervention: pH management group
Number of subjects: 2992
Study: 19347696

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) adaptation of the Coping with Stress program, duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study: 16626410

Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg once daily
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Enoxaparin 30 mg twice daily
Number of subjects: 1000
Study: 15518064

Group type: EXPERIMENTAL
Intervention: Engerix B (37 persons)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Twinrix (35 persons)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 72
Study: 10910900

Group type: EXPERIMENTAL
Intervention: Flt3 ligand (FL) administration
Number of subjects: 0
Study: 9308064

Group type: EXPERIMENTAL
Intervention: Acetaminophen 15 mg.kg‐1
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ibuprofen 10 mg.kg‐1
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 8467623

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil (400 mg orally with food twice a day)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Cefaclor (500 mg orally, fasting, three times a day)
Number of subjects: 371
Study: 31189279

Group type: EXPERIMENTAL
Intervention: Light-emitting diode light phototherapy
Number of subjects: 460

Group type: COMPARATOR
Intervention: Fluorescent light phototherapy
Number of subjects: 460
Study: 28675116

Group type: EXPERIMENTAL
Intervention: Alcohol infusion
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 51
Study: 24077127

Group type: EXPERIMENTAL
Intervention: Medical compression stockings (18 mm of Hg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inner sole
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both treatments together
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 24
Study: 22790511

Group type: EXPERIMENTAL
Intervention: Women (n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Men (n=25)
Number of subjects: 50
Study: 21972403

Group type: EXPERIMENTAL
Intervention: Preprocedure and postprocedure hydration of sodium bicarbonate (early hydration group)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Postprocedure hydration of isotonic saline (late hydration group)
Number of subjects: 450

Group type: COMPARATOR
Intervention: No hydration (control group)
Number of subjects: 450
Study: 19928484

Group type: EXPERIMENTAL
Intervention: Diet and exercise intervention (experimental)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Injury prevention (control)
Number of subjects: 117
Study: 16467022

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg daily (standard regimen)
Number of subjects: 2005

Group type: COMPARATOR
Intervention: Intermittent terbinafine 350 mg daily for 2 weeks on, 2 weeks off
Number of subjects: 2005
Study: 15221928

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy
Number of subjects: 3600

Group type: EXPERIMENTAL
Intervention: Completion lymphadenectomy
Number of subjects: 3600

Group type: EXPERIMENTAL
Intervention: Molecular staging
Number of subjects: 3600

Group type: EXPERIMENTAL
Intervention: Early therapeutic lymphadenectomy and adjuvant interferon alfa‐2b therapy
Number of subjects: 3600
Study: 11534891

Group type: EXPERIMENTAL
Intervention: Formoterol used as needed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single doses of formoterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated dosing of formoterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formoterol for acute asthma attacks
Number of subjects: 0
Study: 9296944

Group type: EXPERIMENTAL
Intervention: Primary hypertension group (35 women)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (30 healthy women)
Number of subjects: 65
Study: 8422839

Group type: EXPERIMENTAL
Intervention: Three-injection regimen (regular prebreakfast, regular prelunch, and [regular+ultralente] predinner)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Two-injection regimen ([regular+intermediary] prebreakfast and predinner)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Three-injection regimen
Number of subjects: 205

Group type: COMPARATOR
Intervention: Three-injection regimen and Two-injection regimen
Number of subjects: 205
Study: 3788652

Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Flupenthixol decanoate
Number of subjects: 32
Study: 30281183

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: MI Varnish application
Number of subjects: 12
Study: 27577546

Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 25
Study: 25240121

Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation (t-VNS) in the Ramsay-Hunt zone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Earlobe stimulation (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (t-VNS and control)
Number of subjects: 60
Study: 22333561

Group type: EXPERIMENTAL
Intervention: FARES method
Number of subjects: 160

Group type: COMPARATOR
Intervention: Eachempati external rotation method
Number of subjects: 160
Study: 20595309

Group type: EXPERIMENTAL
Intervention: Graphical display (sparklines)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional table display
Number of subjects: 12
Study: 18520178

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with cedar pollen extract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cypress pollen specific IgE antibodies
Number of subjects: 0
Study: 16870050

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 10
Study: 14504627

Group type: EXPERIMENTAL
Intervention: High group (individual face-to-face counselling up to 1 hour monthly for 1 year)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Low group (one face-to-face individual counselling session, then monthly telephone contacts for 1 year)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group (usual care only)
Number of subjects: 212
Study: 10781855

Group type: EXPERIMENTAL
Intervention: MenC
Number of subjects: 182

Group type: COMPARATOR
Intervention: MenPS
Number of subjects: 182
Study: 8899756

Group type: EXPERIMENTAL
Intervention: Heparinized saline flush (2.5 ml, 100 U/ml)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normal saline flush (5 ml)
Number of subjects: 51
Study: 1999942

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 0
Study: 6846212

Group type: EXPERIMENTAL
Intervention: 7.5% fructose diet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 15% fructose diet
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0% fructose diet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fructose diets (7.5% and 15%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (normal insulin responses)
Number of subjects: 24